Compare Fiverr International Ltd (FVRR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs GSK plc — how do they compare? Fiverr International Ltd trades at $11.61 (market cap $404.45M), while GSK plc trades at $52.39 (market cap $101.34B). The key difference: GSK plc is far larger — about 250.6× Fiverr International Ltd's market cap, and GSK plc pays a 3.49% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| FVRR | GSK | |
|---|---|---|
Market Cap | $404.45M | $101.34B |
Sector | Industrials | Health |
52-Week High | $26.67 | $61.18 |
52-Week Low | $9.62 | $36.20 |
Enterprise Value | $135.05M | $121.95B |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $11.07, down 1.77% on the day, with a bullish technical signal from moving averages. The company reported revenue of $430.91M in 2025, with net income of $20.98M and improving profit margins. Recent earnings show a mix of beats and one miss, with Q2 2026 results expected soon. Analyst sentiment is mixed, with 41.18% buy ratings and no sell ratings.
The outlook hinges on execution of its strategy shift amid competitive pressures. Risks include declining active buyers and a pending legal investigation. Upside potential exists if spending per buyer growth continues and the company returns to consistent earnings beats, but investor caution is warranted near the 52-week low.
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
